CVKD
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Cadrenal Therapeutics reported a positive FDA Type D meeting outcome supporting the Phase 3 registration study of CAD-1005 in heparin-induced thrombocytopeniaAug 31, 2026
- Cadrenal Therapeutics strengthened its multi-indication strategy for CAD-1005 following a competitor's Phase 3 discontinuationAug 3, 2026
- Cadrenal completed an end-of-Phase 2 meeting with the FDA and outlined a Phase 3 pathway for CAD-1005 in HITApr 30, 2026
- Cadrenal Therapeutics acquires VLX-1005, first-in-class Phase 2 12-LOX inhibitor for heparin-induced thrombocytopeniaDec 11, 2025
- Cadrenal Therapeutics announces clinical trial initiation plans for Tecarfarin in end-stage kidney disease patients transitioning to dialysisAug 5, 2025